Phase 2 Mirvetuximab Soravtansine ADC Targeting FOLR1 with Tubulin Inhibition

This randomized Phase 2 study evaluates the safety and efficacy of mirvetuximab soravtansine, an antibody-drug conjugate delivering DM4 (a tubulin inhibitor) to tumors expressing high folate receptor alpha in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. The trial compares two dosing schedules and includes a hepatic impairment cohort to determine optimal dosing, with AbbVie sponsoring the study.